MX2019008536A - Aglutinantes de albumina serica mejorados. - Google Patents
Aglutinantes de albumina serica mejorados.Info
- Publication number
- MX2019008536A MX2019008536A MX2019008536A MX2019008536A MX2019008536A MX 2019008536 A MX2019008536 A MX 2019008536A MX 2019008536 A MX2019008536 A MX 2019008536A MX 2019008536 A MX2019008536 A MX 2019008536A MX 2019008536 A MX2019008536 A MX 2019008536A
- Authority
- MX
- Mexico
- Prior art keywords
- serum albumin
- relates
- variable domains
- improved serum
- single variable
- Prior art date
Links
- 102000007562 Serum Albumin Human genes 0.000 title abstract 4
- 108010071390 Serum Albumin Proteins 0.000 title abstract 4
- 239000011230 binding agent Substances 0.000 title 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 3
- 102000018358 immunoglobulin Human genes 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000005829 chemical entities Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762446992P | 2017-01-17 | 2017-01-17 | |
| PCT/EP2018/051082 WO2018134234A1 (en) | 2017-01-17 | 2018-01-17 | Improved serum albumin binders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019008536A true MX2019008536A (es) | 2019-09-10 |
Family
ID=61163666
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019008536A MX2019008536A (es) | 2017-01-17 | 2018-01-17 | Aglutinantes de albumina serica mejorados. |
| MX2025010630A MX2025010630A (es) | 2017-01-17 | 2019-07-17 | Aglutinantes de albumina serica mejorados |
| MX2024013316A MX2024013316A (es) | 2017-01-17 | 2019-07-17 | Aglutinantes de albumina serica mejorados |
| MX2024008521A MX2024008521A (es) | 2017-01-17 | 2019-07-17 | Aglutinantes de albumina serica mejorados. |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025010630A MX2025010630A (es) | 2017-01-17 | 2019-07-17 | Aglutinantes de albumina serica mejorados |
| MX2024013316A MX2024013316A (es) | 2017-01-17 | 2019-07-17 | Aglutinantes de albumina serica mejorados |
| MX2024008521A MX2024008521A (es) | 2017-01-17 | 2019-07-17 | Aglutinantes de albumina serica mejorados. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11897944B2 (enExample) |
| EP (3) | EP3571224B1 (enExample) |
| JP (3) | JP7300385B2 (enExample) |
| KR (2) | KR102653724B1 (enExample) |
| CN (2) | CN110461870B (enExample) |
| AU (2) | AU2018209150B2 (enExample) |
| BR (1) | BR112019014600A2 (enExample) |
| CA (1) | CA3050574A1 (enExample) |
| DK (1) | DK3571224T3 (enExample) |
| ES (1) | ES2994387T3 (enExample) |
| FI (1) | FI3571224T3 (enExample) |
| HR (1) | HRP20241501T1 (enExample) |
| HU (1) | HUE068820T2 (enExample) |
| IL (3) | IL316293A (enExample) |
| LT (1) | LT3571224T (enExample) |
| MX (4) | MX2019008536A (enExample) |
| PL (1) | PL3571224T3 (enExample) |
| PT (1) | PT3571224T (enExample) |
| RS (1) | RS66173B1 (enExample) |
| SG (2) | SG10202108973SA (enExample) |
| SI (1) | SI3571224T1 (enExample) |
| WO (1) | WO2018134234A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL318433A (en) | 2014-05-16 | 2025-03-01 | Ablynx Nv | Improved immunoglobulin variable complexes |
| RS63085B1 (sr) | 2014-05-16 | 2022-04-29 | Ablynx Nv | Varijabilni domeni imunoglobulina |
| WO2018104444A1 (en) * | 2016-12-07 | 2018-06-14 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
| WO2018134234A1 (en) * | 2017-01-17 | 2018-07-26 | Ablynx Nv | Improved serum albumin binders |
| DK3571225T3 (da) * | 2017-01-17 | 2024-11-04 | Ablynx Nv | Forbedrede serumalbuminbindere |
| PH12022551214A1 (en) | 2019-12-06 | 2023-10-09 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting tnf# and il-23 |
| WO2021110817A1 (en) | 2019-12-06 | 2021-06-10 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l |
| WO2021116182A1 (en) | 2019-12-09 | 2021-06-17 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp |
| MX2022012278A (es) | 2020-03-30 | 2022-10-27 | Ablynx Nv | Metodo para la produccion y purificacion de dominios variables unicos de inmunoglobulina multivalentes. |
| MX2023003522A (es) | 2020-09-25 | 2023-04-19 | Ablynx Nv | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y ox40l. |
| CN115244076B (zh) * | 2020-10-27 | 2023-08-04 | 北京质肽生物医药科技有限公司 | Gdf15融合蛋白及其用途 |
| AU2021402090A1 (en) | 2020-12-18 | 2023-08-03 | Ablynx Nv | T cell recruiting polypeptides based on tcr alpha/beta reactivity |
| WO2022129572A1 (en) | 2020-12-18 | 2022-06-23 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha |
| KR20230123495A (ko) | 2020-12-18 | 2023-08-23 | 아블린쓰 엔.브이. | 글리피칸-3 및 t세포 수용체를 표적으로 하는 면역글로불린단일 가변 도메인을 포함하는 폴리펩티드 |
| WO2023111266A1 (en) | 2021-12-17 | 2023-06-22 | Ablynx Nv | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123 |
| EP4529540A1 (en) * | 2022-05-23 | 2025-04-02 | Cereius, Inc. | Her2-binding agents and uses thereof |
| IL317588A (en) | 2022-06-14 | 2025-02-01 | Ablynx Nv | Single immunoglobulin variable sites targeting the T cell receptor |
| KR20250042176A (ko) | 2022-07-27 | 2025-03-26 | 아블린쓰 | 신생아 fc 수용체의 특정 에피토프에 결합하는 폴리펩타이드 |
| TW202440614A (zh) | 2022-12-23 | 2024-10-16 | 比利時商艾伯霖克斯公司 | 基於蛋白質的接合載體 |
| KR20250133750A (ko) | 2023-01-09 | 2025-09-08 | 오디세이 테라퓨틱스, 인코포레이티드 | 항-tnfr2 항원-결합 단백질 및 그의 용도 |
| WO2024170756A1 (en) | 2023-02-17 | 2024-08-22 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
| AU2024234615A1 (en) | 2023-03-14 | 2025-08-21 | Odyssey Therapeutics, Inc. | Anti-cd25 antigen-binding proteins and uses thereof |
| AU2024273077A1 (en) | 2023-05-17 | 2025-11-13 | Odyssey Therapeutics, Inc. | Modified single-domain antibodies |
| WO2024261235A1 (en) | 2023-06-22 | 2024-12-26 | Ablynx Nv | Chimeric proteins for modulating cytokine receptor activity |
| TW202515917A (zh) | 2023-06-29 | 2025-04-16 | 美商奧迪希治療公司 | 抗trailr2抗原結合蛋白及其用途 |
| AR133188A1 (es) | 2023-07-05 | 2025-09-03 | Ablynx Nv | ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG |
| WO2025051767A1 (en) | 2023-09-04 | 2025-03-13 | Sanofi | Polypeptides for use in the treatment of glypican-3-expressing tumours |
| TW202532432A (zh) | 2023-09-22 | 2025-08-16 | 比利時商艾伯霖克斯公司 | 二及多價白蛋白結合劑 |
| WO2025080751A2 (en) | 2023-10-13 | 2025-04-17 | Odyssey Therapeutics, Inc. | Anti-cdh17 antigen-binding proteins and uses thereof |
| WO2025099632A1 (en) | 2023-11-08 | 2025-05-15 | Sanofi | Cd25 based lysosomal degrader and uses thereof |
| US20250296991A1 (en) | 2023-12-01 | 2025-09-25 | Ablynx N.V. | Precision activated polypeptides |
| WO2025133166A1 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based carriers for site-specific amine conjugation |
| WO2025133253A2 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based conjugation carriers for intranuclear delivery |
| WO2025217240A1 (en) | 2024-04-10 | 2025-10-16 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| WO2025255558A2 (en) | 2024-06-07 | 2025-12-11 | Odyssey Therapeutics, Inc. | Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof |
| WO2025255435A2 (en) | 2024-06-07 | 2025-12-11 | Odyssey Therapeutics, Inc. | Antigen-binding proteins against serum albumin and uses thereof |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| CN1203178C (zh) | 1997-10-27 | 2005-05-25 | 尤尼利弗公司 | 多价抗原结合蛋白 |
| US6742038B2 (en) | 2000-04-07 | 2004-05-25 | Danger, Inc. | System and method of linking user identification to a subscriber identification module |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| DK1517921T3 (da) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| EP3299393A1 (en) | 2002-11-08 | 2018-03-28 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| CA2512545C (en) | 2003-01-10 | 2015-06-30 | Karen Silence | Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf) |
| MX2007006593A (es) | 2004-12-02 | 2008-03-04 | Domantis Ltd | Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos. |
| CN103254309B (zh) | 2005-05-18 | 2017-09-26 | 埃博灵克斯股份有限公司 | 针对肿瘤坏死因子α的改进的纳米体TM |
| RU2433139C2 (ru) | 2005-05-20 | 2011-11-10 | Аблинкс Н.В. | Nanobodies tm для лечения заболеваний, опосредованных агрегацией |
| WO2007063311A2 (en) | 2005-12-01 | 2007-06-07 | Domantis Limited | Competitive domain antibody formats that bind interleukin 1 receptor type 1 |
| EP1957536A2 (en) | 2005-12-01 | 2008-08-20 | Domantis Limited | Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1 |
| FR2894741B1 (fr) | 2005-12-08 | 2009-12-04 | Centre Nat Etd Spatiales | Chaine de reception par satellite |
| WO2007085814A1 (en) | 2006-01-24 | 2007-08-02 | Domantis Limited | Fusion proteins that contain natural junctions |
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン．ヴェー． | Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| JP2010502208A (ja) | 2006-09-08 | 2010-01-28 | アブリンクス エン．ヴェー． | 半減期の長い血清アルブミン結合タンパク質 |
| EP2152747B1 (en) | 2007-05-24 | 2018-01-03 | Ablynx N.V. | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
| MX2010005783A (es) | 2007-11-27 | 2010-08-10 | Ablynx Nv | Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas. |
| DE102008023620A1 (de) | 2008-05-15 | 2009-11-19 | Mettler-Toledo (Albstadt) Gmbh | Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf |
| BRPI0911984A2 (pt) | 2008-05-16 | 2016-09-20 | Ablynx Nv | sequências de aminoácidos direncionadas contra cxcr4 e outros compostos gpcrs compreendendo os mesmos |
| CA2737241C (en) * | 2008-09-26 | 2017-08-29 | Ucb Pharma S.A. | Multivalent antibody fusion proteins |
| WO2010130832A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions |
| JP2012532620A (ja) | 2009-07-16 | 2012-12-20 | グラクソ グループ リミテッド | 改良型抗血清アルブミン結合単一可変ドメイン |
| CN102666586A (zh) | 2009-09-30 | 2012-09-12 | 葛兰素集团有限公司 | 具有延长的半衰期的药物融合体和缀合物 |
| US9012609B2 (en) | 2010-08-13 | 2015-04-21 | Glaxosmithkline Intellectual Property Development Limited | Anti-serum albumin binding variants |
| SG188204A1 (en) | 2010-08-20 | 2013-04-30 | Glaxo Group Ltd | Improved anti-serum albumin binding variants |
| WO2012042026A1 (en) * | 2010-09-30 | 2012-04-05 | Ablynx Nv | Biological materials related to c-met |
| US11644471B2 (en) * | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| CN106046168A (zh) * | 2011-06-23 | 2016-10-26 | 埃博灵克斯股份有限公司 | 结合血清白蛋白的蛋白 |
| SG194982A1 (en) | 2011-06-23 | 2013-12-30 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| US20150344568A1 (en) * | 2011-06-23 | 2015-12-03 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| WO2012174741A1 (en) | 2011-06-24 | 2012-12-27 | Google Inc. | Determining cross-language query suggestion based on query translations |
| UA118833C2 (uk) | 2011-08-17 | 2019-03-25 | Ґлаксо Ґруп Лімітед | Одиничний варіабельний домен імуноглобуліну, який зв'язується з tnfr1 |
| US20130129727A1 (en) | 2011-11-17 | 2013-05-23 | Nanjingjinsirui Science & Technology Biology Corporation | Methods and systems for increasing protein stability |
| WO2014037419A1 (en) * | 2012-09-04 | 2014-03-13 | Vib Vzw | Immunoglobulin single variable domains directed against cd74 and uses derived thereof |
| US20140186365A1 (en) * | 2013-01-03 | 2014-07-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Antibodies that specifically bind to serum albumin without interfering with albumin's capability to interact with the fcrn |
| WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
| RS63085B1 (sr) | 2014-05-16 | 2022-04-29 | Ablynx Nv | Varijabilni domeni imunoglobulina |
| EP3247407A4 (en) | 2015-01-21 | 2018-08-22 | Inhibrx LP | Non-immunogenic single domain antibodies |
| ES2754427T3 (es) | 2015-05-13 | 2020-04-17 | Ablynx Nv | Polipéptidos de reclutamiento de células T basados en la reactividad de TCR alfa/beta |
| CN118846026A (zh) | 2015-10-22 | 2024-10-29 | 摩登纳特斯有限公司 | 广谱流感病毒疫苗 |
| SG11201803976VA (en) | 2015-11-27 | 2018-06-28 | Ablynx Nv | Polypeptides inhibiting cd40l |
| US11299751B2 (en) * | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2018104444A1 (en) * | 2016-12-07 | 2018-06-14 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
| DK3571225T3 (da) * | 2017-01-17 | 2024-11-04 | Ablynx Nv | Forbedrede serumalbuminbindere |
| WO2018134234A1 (en) | 2017-01-17 | 2018-07-26 | Ablynx Nv | Improved serum albumin binders |
-
2018
- 2018-01-17 WO PCT/EP2018/051082 patent/WO2018134234A1/en not_active Ceased
- 2018-01-17 RS RS20241239A patent/RS66173B1/sr unknown
- 2018-01-17 BR BR112019014600-8A patent/BR112019014600A2/pt unknown
- 2018-01-17 SG SG10202108973SA patent/SG10202108973SA/en unknown
- 2018-01-17 HU HUE18703213A patent/HUE068820T2/hu unknown
- 2018-01-17 IL IL316293A patent/IL316293A/en unknown
- 2018-01-17 EP EP18703213.1A patent/EP3571224B1/en active Active
- 2018-01-17 HR HRP20241501TT patent/HRP20241501T1/hr unknown
- 2018-01-17 CN CN201880015687.2A patent/CN110461870B/zh active Active
- 2018-01-17 KR KR1020197024114A patent/KR102653724B1/ko active Active
- 2018-01-17 FI FIEP18703213.1T patent/FI3571224T3/fi active
- 2018-01-17 LT LTEPPCT/EP2018/051082T patent/LT3571224T/lt unknown
- 2018-01-17 AU AU2018209150A patent/AU2018209150B2/en active Active
- 2018-01-17 EP EP24191390.4A patent/EP4442708A3/en active Pending
- 2018-01-17 PT PT187032131T patent/PT3571224T/pt unknown
- 2018-01-17 IL IL305912A patent/IL305912B2/en unknown
- 2018-01-17 CA CA3050574A patent/CA3050574A1/en active Pending
- 2018-01-17 DK DK18703213.1T patent/DK3571224T3/da active
- 2018-01-17 SG SG11201906341XA patent/SG11201906341XA/en unknown
- 2018-01-17 PL PL18703213.1T patent/PL3571224T3/pl unknown
- 2018-01-17 IL IL267897A patent/IL267897B2/en unknown
- 2018-01-17 CN CN202311114345.5A patent/CN117327175A/zh active Pending
- 2018-01-17 EP EP24191396.1A patent/EP4471058A3/en active Pending
- 2018-01-17 KR KR1020237040677A patent/KR20230165374A/ko not_active Ceased
- 2018-01-17 US US16/477,927 patent/US11897944B2/en active Active
- 2018-01-17 ES ES18703213T patent/ES2994387T3/es active Active
- 2018-01-17 JP JP2019538383A patent/JP7300385B2/ja active Active
- 2018-01-17 SI SI201831172T patent/SI3571224T1/sl unknown
- 2018-01-17 MX MX2019008536A patent/MX2019008536A/es unknown
-
2019
- 2019-07-17 MX MX2025010630A patent/MX2025010630A/es unknown
- 2019-07-17 MX MX2024013316A patent/MX2024013316A/es unknown
- 2019-07-17 MX MX2024008521A patent/MX2024008521A/es unknown
-
2022
- 2022-10-20 JP JP2022168448A patent/JP7585272B2/ja active Active
-
2024
- 2024-01-04 US US18/404,145 patent/US20240294617A1/en active Pending
- 2024-11-06 JP JP2024194438A patent/JP2025024012A/ja active Pending
-
2025
- 2025-04-07 AU AU2025202453A patent/AU2025202453A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023005374A (es) | Aglutinantes de albumina serica mejorados. | |
| MX2025010630A (es) | Aglutinantes de albumina serica mejorados | |
| MX2023003630A (es) | Aglutinantes de albumina de suero mejorados. | |
| WO2017085172A3 (en) | Improved serum albumin binders | |
| MX2022009306A (es) | Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos. | |
| EA201892691A1 (ru) | Однодоменный белок, связывающий сывороточный альбумин | |
| PH12018501025A1 (en) | Improved tnf binders | |
| WO2019195623A3 (en) | Heterodimeric antibodies that bind fibroblast activation protein | |
| PH12018502182A1 (en) | Trispecific and/or trivalent binding proteins | |
| EA201990321A1 (ru) | Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123 | |
| MY194290A (en) | CD123 Binding Proteins and Related Compositions and Methods | |
| EA201890613A1 (ru) | Полипептиды, связывающие cd3 | |
| EA201791666A1 (ru) | Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123 | |
| ZA202000961B (en) | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods | |
| HK1258507A1 (zh) | 改进的p2x7受体结合剂和包含其的多肽 | |
| MX2023004804A (es) | Proteinas de union triespecificas y/o trivalentes. | |
| EA202090617A1 (ru) | Варианты антител | |
| EA202090727A1 (ru) | Варианты антител | |
| TH148296B (th) | แอนติบอดีต้านเมทริกซ์เมทัลโลโปรตีเนส 9 (Antibodies to matrix metalloproteinase 9) | |
| EA201990773A1 (ru) | Cd123-связывающие белки и относящиеся к ним композиции и способы | |
| TN2018000345A1 (en) | Trispecific and/or trivalent binding proteins |